



(12) Translation of  
European patent specification

(11) NO/EP 3740481 B1

NORWAY

(19)	NO	
(51)	Int Cl.	
	C07D 403/12 (2006.01)	C07D 401/12 (2006.01)
	A61K 31/4196 (2006.01)	C07D 413/04 (2006.01)
	A61P 9/04 (2006.01)	C07D 413/12 (2006.01)
	C07D 231/14 (2006.01)	C07D 413/14 (2006.01)
	C07D 271/06 (2006.01)	C07D 417/12 (2006.01)

**Norwegian Industrial Property Office**

---

(45)	Translation Published	2024.09.02
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.06.26
(86)	European Application Nr.	19703917.5
(86)	European Filing Date	2019.01.18
(87)	The European Application's Publication Date	2020.11.25
(30)	Priority	2018.01.19, US, 201862619643 P 2018.10.15, US, 201862745724 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
	Designated Validation States:	KH ; MA ; MD ; TN
(73)	Proprietor	Cytokinetics, Inc., 350 Oyster Point Blvd, South San Francisco CA 94080, USA
(72)	Inventor	CHUANG, Chihyuan, 460 Bayview Avenue, Milbrae, California 94030, USA MORGAN, Bradley P., 5948 Monzal Avenue, Oakland, California 94611, USA VANDERWAL, Mark, 6132 Johnston Drive, Oakland, California 94611, USA WANG, Wenyue, 1028 The Dalles Avenue, Sunnyvale, California 94087, USA ASHCRAFT, Luke W., 668 Carolina Street, San Francisco, California 94107, USA
(74)	Agent or Attorney	ZACCO NORWAY AS, Postboks 488, 0213 OSLO, Norge


---

(54)	Title	DIHYDROBENZOFURAN AND INDEN ANALOGS AS CARDIAC SARCOMERE INHIBITORS
(56)	References Cited:	WO-A2-2006/009726 WO-A2-2007/078815 WO-A2-2012/101011 WO-A2-2010/033701 WO-A2-2004/064730 PAM R. TAUB ET AL: "Perturbations in skeletal muscle sarcomere structure in patients with heart failure and Type 2 diabetes: restorative effects of (-)-epicatechinrich cocoa", CLINICAL SCIENCE., vol. 125, no. 8, 1 October 2013 (2013-10-01), GB, pages 383 - 389, XP055568949, ISSN: 0143-5221, DOI: 10.1042/CS20130023

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

**Patentkrav**

1. En forbindelse med formel (I), eller et farmasøytisk akseptabelt salt derav:



5 (I),

hvor:

G<sub>1</sub> er -CR<sup>4</sup>R<sup>5</sup>-;

G<sub>2</sub> er en binding;

G<sub>3</sub> er -CR<sup>8</sup>- eller -N-;

10 R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, og R<sup>8</sup> er hver uavhengig H, C<sub>1</sub>-C<sub>6</sub> alkyl, halo, eller hydroksyl;

R<sup>2</sup> er H, C<sub>2</sub>-C<sub>6</sub> alkyl, halo, eller hydroksyl;

15 Z er valgt fra gruppen som består av en binding, C<sub>1</sub>-C<sub>6</sub> alkyl, -O-, -R<sup>X</sup>O-, og - OR<sup>Y</sup>-;

A er valgt fra gruppen som består av usubstituert fenyld, og 5- eller 6-leddet heteroaryl som omfatter minst ett ringformet N-atom, hvor 5- eller 6-leddet heteroaryl er usubstituert eller substituert med én eller flere R<sup>10</sup> substituenter;


20 hver R<sup>10</sup> er uavhengig valgt fra gruppen som består av -C(O)OCH<sub>3</sub>, methyl, etyl, isopropyl, difluormetyl, syklopropyl, syklobutyl, og oksetanyl, hvor hver methyl, etyl og isopropyl av R<sup>10</sup> er uavhengig usubstituert eller substituert med én flere substituenter uavhengig valgt fra gruppen som består av -OCH<sub>3</sub>, -OH, og -OC(O)CH<sub>3</sub>;

25 B er valgt fra gruppen som består av H, C<sub>1</sub>-C<sub>6</sub> alkyl, sykloalkyl, aryl, heterosykloalkyl, og heteroaryl, hvor the C<sub>1</sub>-C<sub>6</sub> alkyl, sykloalkyl, aryl, heterosykloalkyl, eller heteroaryl av B er usubstituert eller substituert med én eller flere R<sup>11</sup> substituenter;

hver R<sup>11</sup> er uavhengig valgt fra gruppen som består av substituert eller usubstituert heterosykloalkyl, substituert eller usubstituert heteroaryl, substituert eller usubstituert sykloalkyl, substituert eller usubstituert aryl,

- usubstituert C<sub>1</sub>-C<sub>6</sub> alkyl, Ci-C<sub>6</sub> alkyl substituert med én eller flere R<sup>12</sup> substituenter, substituert eller usubstituert C<sub>2</sub>-C<sub>6</sub> alkenyl, substituert eller usubstituert C<sub>2</sub>-C<sub>6</sub> alkynyl, halo, -OR<sup>b</sup>, -C(O)R<sup>c</sup>, -C(O)OR<sup>d</sup>, okso, og -NR<sup>e</sup>R<sup>f</sup>;
- 5       hver R<sup>12</sup> er uavhengig valgt fra gruppen som består av halo, -OR<sup>b</sup>, -C(O)R<sup>g</sup>, -C(O)OR<sup>h</sup>, og -C(O)NR<sup>i</sup>R<sup>j</sup>;
- hver R<sup>b</sup>, R<sup>c</sup>, R<sup>d</sup>, R<sup>e</sup>, R<sup>f</sup>, R<sup>g</sup>, R<sup>h</sup>, og R<sup>j</sup> er uavhengig H eller C<sub>1</sub>-C<sub>6</sub> alkyl; og R<sup>x</sup> og R<sup>y</sup> er hver C<sub>1</sub>-C<sub>6</sub> alkyl,
- hvor når A er usubstituert fenyl, er -Z-B enheten ikke -OC(CH<sub>3</sub>)<sub>3</sub> eller 1-ethyl-3-hydroksy-1,5-dihydro-2H-pyrrol-2-onyl.
- 10

**2.** Forbindelsen ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, hvor forbindelsen med formel (I) er en forbindelse med formel (If):



- 3.** Forbindelsen ifølge krav 1 eller krav 2, eller et farmasøytisk akseptabelt salt derav, hvor R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, og R<sup>8</sup> er hver H.
- 20     **4.** Forbindelsen ifølge krav 1 eller krav 2, eller et farmasøytisk akseptabelt salt derav, hvor G<sub>1</sub> er -CH<sub>2</sub>-.
- 5.** Forbindelsen ifølge et hvilket som helst av krav 1 til 4, eller et farmasøytisk akseptabelt salt derav, hvor G<sub>3</sub> er -CR<sup>8</sup>-, for eksempel, hvor G<sub>3</sub> er -CH-.
- 25     **6.** Forbindelsen ifølge et hvilket som helst av krav 1, 2, 4, eller 5, hvor R<sup>1</sup>, R<sup>2</sup>, og R<sup>3</sup> er hver H.
- 7.** Forbindelsen ifølge et hvilket som helst av krav 1 til 6, eller et farmasøytisk akseptabelt salt derav, hvor Z er en binding.
- 30

**8.** Forbindelsen ifølge et hvilket som helst av krav 1 til 6, eller et farmasøytsk akseptabelt salt derav, hvor Z er -O-.




**9.** Forbindelsen ifølge et hvilket som helst av krav 1 til 8, eller et farmasøytsk  
5 akseptabelt salt derav, hvor A er valgt fra

(a) gruppen som består av pyrazolyl, oksazolyl, oksadiazolyl, isoksazolyl, tetrazolyl, triazolyl, tiazolyl, pyrimidinyl, pyridinyl, pyrazinyl, pyridazinyl, hver av hvilke er usubstituert eller substituert med én eller flere R<sup>10</sup> substituenter, og usubstituert fenyl.


10 eventuell

hvor A er oksadiazolyl eller isoksazolyl, hver av hvilke er usubstituert eller substituert med én eller flere  $R^{10}$  substituenter, eller

(b) gruppen som består av:



hver av hvilke er usubstituert eller substituert med én eller flere R<sup>10</sup>-substituenter, og



25

**10.** Forbindelsen ifølge et hvilket som helst av krav 1 til 9, eller et farmasøytsk akseptabelt salt derav, hvor

(a) A er oksadiazolyl, som er usubstituert eller substituert med én substituent valgt fra gruppen som består av methyl, methyl substituert med  $-\text{OCH}_3$ ,  $-\text{OH}$ , eller  $-\text{OC(O)CH}_3$ , etyl, etyl substituert med  $-\text{OCH}_3$ ,  $-\text{OH}$ , eller





-OC(O)CH<sub>3</sub>, isopropyl, isopropyl substituert med -OCH<sub>3</sub>, -OH, eller -OC(O)CH<sub>3</sub>, difluormetyl, syklopropyl, syklobutyl, oksetanyl, og -C(O)OCH<sub>3</sub>, eller

- 5 (b) A er oksadiazolyl, som er usubstituert eller substituert med én substituent valgt fra gruppen som består av methyl, etyl, isopropyl, difluormetyl, syklopropyl, og syklobutyl.

**11.** Forbindelsen ifølge et hvilket som helst av krav 1 til 9, eller et farmasøytisk akseptabelt salt derav, hvor

- 10 (a) A er isoksazolyl, som er usubstituert eller substituert med én eller flere substituenter valgt fra gruppen som består av methyl, etyl, og difluormetyl, eller  
 (b) A er isoksazolyl, som er usubstituert eller substituert med én substituent valgt fra gruppen som består av methyl, etyl, og difluormetyl.

- 15 **12.** Forbindelsen ifølge et hvilket som helst av krav 1 til 9, eller et farmasøytisk akseptabelt salt derav, hvor A er valgt fra gruppen som består av:




5 hvor hver R<sup>13</sup> er uavhengig valgt fra gruppen som består av H, -C(O)OCH<sub>3</sub>, methyl, etyl, isopropyl, difluormetyl, syklopropyl, syklobutyl, og oksetanyl, hvor hver methyl, etyl og isopropyl av R<sup>13</sup> er uavhengig usubstituert eller substituert med én eller flere substituenter uavhengig valgt fra gruppen som består av - OCH<sub>3</sub>, -OH, og -OC(O)CH<sub>3</sub>.

**13.** Forbindelsen ifølge et hvilket som helst av krav 1 til 12, eller et farmasøytsk akseptabelt salt derav, hvor B er valgt fra gruppen som består av

- 10 (a) R, C<sub>1</sub>-C<sub>6</sub> alkyl, sykloalkyl, aryl, heterosykloalkyl, og heteroaryl, hvor C<sub>1</sub>-C<sub>6</sub> alkyl, sykloalkyl, aryl, heterosykloalkyl, eller heteroaryl av B er usubstituert eller substituert med én eller flere R<sup>11</sup> substituenter; hvor R<sup>11</sup> er uavhengig valgt fra gruppen som består av heterosykloalkyl, heteroaryl, sykloalkyl, aryl, C<sub>1</sub>-C<sub>6</sub> alkyl, halo, fluoralkyl, -OR<sup>b</sup>, -C(O)R<sup>c</sup>, -C(O)OR<sup>d</sup>, okso, og -NR<sup>e</sup>R<sup>f</sup>, hvor hver heterosykloalkyl og heteroaryl av R<sup>11</sup> er usubstituert eller substituert med én eller flere substituenter valgt fra gruppen som består av C<sub>1</sub>-C<sub>6</sub> alkyl, -C(O)R<sup>n</sup>, -C(O)OR<sup>p</sup>, og -C(O)NR<sup>q</sup>R<sup>r</sup>; og hver R<sup>b</sup>, R<sup>c</sup>, R<sup>d</sup>, R<sup>e</sup>, R<sup>f</sup>, R<sup>n</sup>, R<sup>p</sup>, R<sup>q</sup>, og R<sup>r</sup> er uavhengig H eller C<sub>1</sub>-C<sub>6</sub> alkyl, eller
- 15 (b) C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>5</sub> sykloalkyl, 6- til 10-leddet aryl, 4- til 6-leddet heterosykloalkyl som omfatter minst ett ringformet N- eller O-atom, 5- eller 6-leddet monosyklistisk heteroaryl som omfatter minst ett ringformet N-atom, og 8- eller 9-leddet bisyklistisk heteroaryl som omfatter minst ett ringformet N-atom, hver av hvilke er substituert eller usubstituert, eller
- 20 (c) C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>5</sub> sykloalkyl, 6- til 10-leddet aryl, 4- til 6-leddet heterosykloalkyl som omfatter minst ett ringformet N- eller O-atom, 5- eller 6-leddet monosyklistisk heteroaryl som omfatter minst ett ringformet N-atom, eller 8- eller 9-leddet bisyklistisk heteroaryl som omfatter minst ett ringformet N-atom, hver av hvilke er usubstituert eller substituert med én eller flere R<sup>11</sup> substituenter;
- 25 (d) C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>5</sub> sykloalkyl, 6- til 10-leddet aryl, 4- til 6-leddet heterosykloalkyl, heteroaryl, sykloalkyl, aryl, C<sub>1</sub>-C<sub>6</sub> alkyl, halo, fluoralkyl, -OR<sup>b</sup>, -C(O)R<sup>c</sup>, -C(O)OR<sup>d</sup>, okso, og -NR<sup>e</sup>R<sup>f</sup>, hvor hver heterosykloalkyl og heteroaryl av R<sup>11</sup> er usubstituert eller substituert med én eller flere substituenter valgt fra

- gruppen som består av C<sub>1</sub>-C<sub>6</sub> alkyl, -C(O)R<sup>n</sup>, -C(O)OR<sup>p</sup>, og -C(O)NR<sup>q</sup>R<sup>r</sup>, og hvor hver C<sub>1</sub>-C<sub>6</sub> alkyl av R<sup>11</sup> er usubstituert eller substituert med -OR<sup>b</sup>; og hver R<sup>b</sup>, R<sup>c</sup>, R<sup>d</sup>, R<sup>e</sup>, R<sup>f</sup>, R<sup>n</sup>, R<sup>p</sup>, R<sup>q</sup>, og R<sup>r</sup> er uavhengig H eller C<sub>1</sub>-C<sub>6</sub> alkyl, eller
- 5           (d) methyl, etyl, isopropyl, isobutyl, tert-butyl, syklopropyl, syklobutyl, syklopentyl, fenyl, indanyl, azetidinyl, oksetanyl, pyrrolidinyl, tetrahydrofuranyl, piperidinyl, piperazinyl, morfolinyl, tiazolyl, triazolyl, imidazolyl, pyrazolyl, tetrazolyl, oksazolyl, isoksazolyl, oksadiazolyl, pyrazinyl, pyridazinyl, pyrimidinyl, pyridinyl, indanyl, pyrrolopyrazolyl og benzoimidazolyl, hver av hvilke er usubstituert eller substituert med én eller flere R<sup>11</sup> substituenter;
- 10           hver R<sup>11</sup> er uavhengig valgt fra gruppen som består av heterosykloalkyl, heteroaryl, sykloalkyl, aryl, C<sub>1</sub>-C<sub>6</sub> alkyl, halo, fluoralkyl, -OR<sup>b</sup>, -C(O)R<sup>c</sup>, -C(O)OR<sup>d</sup>, okso, og -NR<sup>e</sup>R<sup>f</sup>, hvor hver heterosykloalkyl og heteroaryl av R<sup>11</sup>
- 15           er usubstituert eller substituert med én eller flere substituenter valgt fra gruppen som består av C<sub>1</sub>-C<sub>6</sub> alkyl, -C(O)R<sup>n</sup>, -C(O)OR<sup>p</sup>, og -C(O)NR<sup>q</sup>R<sup>r</sup>, og hvor hver C<sub>1</sub>-C<sub>6</sub> alkyl av R<sup>11</sup> er usubstituert eller substituert med -OR<sup>b</sup>; og hver R<sup>b</sup>, R<sup>c</sup>, R<sup>d</sup>, R<sup>e</sup>, R<sup>f</sup>, R<sup>n</sup>, R<sup>p</sup>, R<sup>q</sup>, og R<sup>r</sup> er uavhengig H eller C<sub>1</sub>-C<sub>6</sub> alkyl.
- 20       **14.** Forbindelsen ifølge hvilket som helst av krav 1 til 13, eller et farmasøytisk akseptabelt salt derav, hvor hver R<sup>11</sup> er uavhengig valgt fra gruppen som består av methyl, etyl, isopropyl, syklopropyl, difluormetyl, trifluormetyl, okso, -C(O)CH<sub>3</sub>, -C(O)OtBu, -OCH<sub>3</sub>, -OH, -NH<sub>2</sub>, -Cl, oksetanyl, oksadiazolyl, og azetidinyl, hvor hver oksadiazolyl og azetidinyl av R<sup>11</sup> er usubstituert eller substituert med én eller flere substituenter valgt fra gruppen som består av etyl, -C(O)CH<sub>3</sub>, -C(O)OtBu, -C(O)OCH<sub>3</sub>, -C(O)NHCH<sub>3</sub>, -C(O)NH<sub>2</sub>, og -OCH<sub>3</sub>, og hvor hver methyl, etyl, og isopropyl av R<sup>11</sup> er usubstituert eller substituert med -OH.
- 25       **15.** Forbindelsen ifølge et hvilket som helst av krav 1 til 12, eller et farmasøytisk akseptabelt salt derav, hvor
- 30           (a) B er methyl, pyrazolyl, oksazolyl, tetrazolyl, isoksazolyl, tiazolyl, imidazolyl, eller pyridinyl, hver av hvilke er usubstituert eller substituert med én eller flere R<sup>11</sup> substituenter;

hver R<sup>11</sup> er uavhengig valgt fra gruppen som består av heterosykloalkyl, heteroaryl, halo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkyl substituert med én eller to R<sup>12</sup> substituenter, sykloalkyl, sykloalkyl substituert med én eller to R<sup>12</sup> substituenter, fluoralkyl, -OR<sup>b</sup>, -C(O)R<sup>c</sup>, -C(O)OR<sup>d</sup>, okso, og -NR<sup>e</sup>R<sup>f</sup>; 5 hver R<sup>12</sup> er uavhengig valgt fra gruppen som består av halo, -OR<sup>b</sup>, -C(O)R<sup>g</sup>, -C(O)OR<sup>b</sup>, og -C(O)NR<sup>i</sup>R<sup>j</sup>; og hver R<sup>b</sup>, R<sup>c</sup>, R<sup>d</sup>, R<sup>e</sup>, og R<sup>f</sup>, R<sup>g</sup>, R<sup>h</sup>, og R<sup>j</sup> er uavhengig H eller C<sub>1</sub>-C<sub>6</sub> alkyl, eller  
(b) B er valgt fra gruppen som består av:





hver av hvilke er usubstituert eller substituert med én eller flere R<sup>11</sup> substituenter;

25       hver R<sup>11</sup> er uavhengig valgt fra gruppen som består av heterosykloalkyl, heteroaryl, halo, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkyl substituert med én eller to

- $R^{12}$  substituenter, sykloalkyl, sykloalkyl substituert med én eller to  $R^{12}$  substituenter, fluoralkyl,  $-OR^b$ ,  $-C(O)R^c$ ,  $-C(O)OR^d$ , okso, og  $-NR^eR^f$ ;  
 hver  $R^{12}$  er uavhengig valgt fra gruppen som består av halo,  $-OR^b$ ,  $-C(O)R^g$ ,  
 $-C(O)OR^h$ , og  $-C(O)NR^iR^j$ ; og  
 5       hver  $R^b$ ,  $R^c$ ,  $R^d$ ,  $R^e$ , og  $R^f$ ,  $R^g$ ,  $R^h$ , og  $R^i$  er uavhengig H eller  $C_1-C_6$  alkyl.

- 16.** Forbindelsen ifølge et hvilket som helst av krav 1 til 12, eller et farmasøytisk akseptabelt salt derav, hvor B er pyrazolyl, oksazolyl, tetrazolyl, isoksazolyl, tiazolyl, imidazolyl, eller pyridinyl, hver av hvilke er usubstituert eller substituert  
 10     med én eller flere  $R^{11}$  substituenter;  
       hver  $R^{11}$  er uavhengig valgt fra gruppen som består av heterosykloalkyl, heteroaryl, halo,  $C_1-C_6$  alkyl,  $C_1-C_6$  alkyl substituert med én eller to  $R^{12}$  substituenter, sykloalkyl, sykloalkyl substituert med én eller to  $R^{12}$  substituenter, fluoralkyl,  $-OR^b$ , okso, og  $-NR^eR^f$ ;  
 15     hver  $R^{12}$  er uavhengig valgt fra gruppen som består av halo,  $-OR^b$ , og  $-C(O)NR^iR^j$ ; og  
       hver  $R^b$ ,  $R^e$ ,  $R^f$ , og  $R^j$  er uavhengig H eller  $C_1-C_6$  alkyl,  
       eventuelt  
       hvor  $R^b$  er H.  
 20





substituert med én eller flere substituenter valgt fra gruppen som består av C<sub>1</sub>-C<sub>6</sub> alkyl, -C(O)R<sup>n</sup>, -C(O)OR<sup>p</sup>, og -C(O)NR<sup>q</sup>R<sup>r</sup>;  
 hver R<sup>12</sup> er uavhengig valgt fra gruppen som består av halo, -OR<sup>b</sup>, -C(O)R<sup>g</sup>,  
 - C(O)OR<sup>b</sup>, og -C(O)NR<sup>i</sup>R<sup>j</sup>; og  
 5 hver R<sup>b</sup>, R<sup>c</sup>, R<sup>d</sup>, R<sup>e</sup>, R<sup>f</sup>, R<sup>g</sup>, R<sup>h</sup>, og R<sup>j</sup>, R<sup>n</sup>, R<sup>p</sup>, R<sup>q</sup>, og R<sup>r</sup> er uavhengig H eller C<sub>1</sub>-C<sub>6</sub> alkyl.

**18.** Forbindelsen ifølge krav 1, hvor forbindelsen er valgt fra gruppen som består av

Forb. nr	Struktur	Navn
1		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2,2-difluoracetamid
2		N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-benzamid
3		2-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-isonikotinamid
4		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-benzamid

Forb. nr	Struktur	Navn
5		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metylisonikotinamid
6		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-metyl-1H-imidazol-5-karboksamid
7		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-metyl-1H-pyrazol-4-karboksamid
8		2-klor-N-(5-(5-(difluor-metyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)tiazol-5-karboksamid
9		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metyloksazol-5-karboksamid

Forb. nr	Struktur	Navn
10		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metyltaiazol-5-karboksamid
11		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-taiazol-5-karboksamid
12		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-metyloksazol-5-karboksamid
16		tert-butyl-(5-(5-(difluor-metyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat
17		N-(3-(5-ethyl-1,2,4-oksa-diazol-3-yl)-6,7-dihydro-5H-syklopenta[b]pyridin-7-yl)benzamid
19		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-

Forb. nr	Struktur	Navn
		yl)-2,4-dimetyloksazol-5-karboksamid
20		N-(5-(5-(difluormethyl)-1,2,4-oxsadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-ethyl-5-methyl-2H-1,2,3-triazol-4-karboksamid
21		4-syklopropyl-N-(5-(5-(difluormethyl)-1,2,4-oxsadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-oksazol-5-karboksamid
22		N-(5-(5-(difluormethyl)-1,2,4-oxsadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2,5-dimetyloksazol-4-karboksamid
23		N-(5-(5-(difluormethyl)-1,2,4-oxsadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-6-metylpyrazin-2-karboksamid

Forb. nr	Struktur	Navn
24		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2,6-dimethylisonicotinamid
25		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-3 - etyl-1-methyl-1H-pyrazol-4-karboksamid
26		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methylpyrimidin-4-karboksamid
27		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,5-dimethyl-1H-pyrazol-4-karboksamid
28		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2,6-dimethylisonicotinamid

Forb. nr	Struktur	Navn
		yl)-1,3-dimetyl-1H-pyrazol-4-karboksamid
29		N-(5-(5-(difluormethyl)-1,2,4-oxsadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-ethyl-1H-pyrazol-5-karboksamid
30		N-(5-(5-(difluormethyl)-1,2,4-oxsadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-5-karboksamid
31		(R)-2-methyl-N-(5-(5-methyl-1,2,4-oxsadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)isonikotinamid
32		(R)-N-(5-(5-(difluormethyl)-1,2,4-oxsadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methylisonikotinamid

Forb. nr	Struktur	Navn
33		2-amino-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-isonikotinamid
34		3-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-isoksazol-5-karboksamid
35		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-5-karboksamid
36		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-5,6-dihydro-4H-pyrrolo-[1,2-b]pyrazol-3-karboksamid
37		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2,3-dihydro-1H-inden-1-yl-isoxazol-5-karboksamid






Forb. nr	Struktur	Navn
		yil)-6-metylpyridazin-4-karboksamid
38		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-3-metylpyrazin-2-karboksamid
39		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metylnicotinamid
40		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-metyl-3-(trifluormethyl)-1H-pyrazol-4-karboksamid
41		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-3,5-dimethylpyrazin-2-karboksamid

Forb. nr	Struktur	Navn
42		N-(3-(5-methyl-1,2,4-oxadiazol-3-yl)-6,7-dihydro-5H-syklopenta[b]pyridin-7-yl)benzamid
43		2-hydroksy-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-isonikotinamid
44		2-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2H-1,2,3-triazol-4-karboksamid
45		1,2-dimethyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-imidazol-5-karboksamid
46		5-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-isoksazol-4-karboksamid






Forb. nr	Struktur	Navn
47		1,3-dimetyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
48		(R)-2-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)oksazol-5-karboksamid
49		N-(5-(5-(difluormetyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
50		N-(5-(5-(difluormetyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
51		4-metyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-oksazol-5-karboksamid

Forb. nr	Struktur	Navn
52		4-syklopropyl-N-(5-(5-methyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)oksazol-5-karboksamid
53		2,4-dimetyl-N-(5-(5-methyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)oksazol-5-karboksamid
54		1,5-dimetyl-N-(5-(5-methyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
55		1,3-dimetyl-N-(5-(5-methyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
56		1-etyl-N-(5-(5-methyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid

Forb. nr	Struktur	Navn
57		N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-5,6-dihydro-4H-pyrrolo[1,2-b]-pyrazol-3-karboksamid
58		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-3-metylpirrolinamid
59		3-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-pikolinamid
60		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-metylthiazol-2-karboksamid
61		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,2-dimethyl-1H-imidazol-5-karboksamid

Forb. nr	Struktur	Navn
63		4-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-thiazolidinone
64		2-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2H-tetrazol-5-karboksamid
65		1-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
66		(R)-1-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
67		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-metylpyridinamid

Forb. nr	Struktur	Navn
68		4-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-pikolinamid
69		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-3-methyl-1H-pyrazol-4-karboksamid
70		3-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
71		(R)-N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-3-methyl-1H-pyrazol-4-karboksamid
72		(R)-N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-5-methylisoxazol-4-karboksamid






Forb. nr	Struktur	Navn
73		N-(5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-4-karboksamid
74		(3-(1-(1,3-dimetyl-1H-pyrazol-4-karboks-amido)-2,3-dihydro-1H-inden-5-yl)-1,2,4-oksadiazol-5-yl)methyl acetat
75		N-(5-(5-isopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-4-karboksamid
76		N-(5-(metoksy-metyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-4-karboksamid
77		(1S)-1-(3-(1-(1,3-dimetyl-1H-pyrazol-4-karboksamido)-2,3-dihydro-1H-inden-5-yl)-1,2,4-oksadiazol-5-yl)-ethylacetat

Forb. nr	Struktur	Navn
78		metyl 3-(1-(1,3-dimethyl-1H-pyrazol-4-karboks-amido)-2,3-dihydro-1H-inden-5-yl)-1,2,4-oksadiazol-5-karboksylat
79		N-(5-(5-(hydroksy-methyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-4-karboksamid
80		N-(5-(5-((S)-1-hydroksyethyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-4-karboksamid
81		N-(5-(difluormethyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metyl-2H-tetrazol-5-karboksamid

Forb. nr	Struktur	Navn
82		(R)-N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-2H-tetrazol-5-karboksamid
83		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-1,2,3-triazol-4-karboksamid
84		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-5-methyl-1,2,4-oxadiazol-3-karboksamid
87		5-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,2,4-oxadiazol-3-karboksamid
88		4-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,2,4-oxadiazol-3-karboksamid

Forb. nr	Struktur	Navn
		yl)isoksazol-5-karboksamid
89		3-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)isoksazol-4-karboksamid
90		(R)-N-(5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-4-karboksamid
91		(R)-N-(5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,5-dimethyl-1H-pyrazol-4-karboksamid
92		(R)-N-(5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-5-karboksamid

Forb. nr	Struktur	Navn
93		(R)-N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-methyl-isoksazol-5-karboksamid
94		N-(3-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-6,7-dihydro-5H-syklopenta[b]pyridin-7-yl)benzamid
95		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-hydroksyisonikotinamid
99		2-amino-N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-isonikotinamid
100		(R)-N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metyl-oksazol-5-karboksamid

Forb. nr	Struktur	Navn
101		(R)-N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-5-karboksamid
102		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-3-methylisoksazol-5-karboksamid
103		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-methylisoksazol-5-karboksamid
104		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-methylisoksazol-3-karboksamid
105		4-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)isoksazol-3-karboksamid

Forb. nr	Struktur	Navn
106		(R)-1,3-dimethyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
107		(R)-1-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
108		N-(3-(5-ethyl-1,2,4-oxadiazol-3-yl)-6,7-dihydro-5H-syklo-penta[b]pyridin-7-yl)-2-metylisonikotinamid
111		(R)-1,3-dimethyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
112		(R)-2,4-dimethyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)oksazol-5-karboksamid

Forb. nr	Struktur	Navn
113		(R)-4-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)isoksazol-5-karboksamid
114		(R)-N-(5-(metoksy-methyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-methyl-isoksazol-5-karboksamid
115		(R)-N-(5-(syklopropyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-metylisoksazol-5-karboksamid
116		(R)-N-(5-(isopropyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-metylisoksazol-5-karboksamid
117		(R)-4-methyl-N-(5-(oksetan-3-yl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-isoksazol-5-karboksamid






Forb. nr	Struktur	Navn
118		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-1,2,4-triazol-3-karboksamid
119		1-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-1,2,4-triazol-3-karboksamid
120		1-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-1,2,4-triazol-5-karboksamid
125		(R)-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-okso-2,3-dihydro-1H-benzo[d]imidazol-5-karboksamid
126		N-((R)-5-(5-((S)-1-metoksyetyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-metylisoksazol-5-karboksamid

Forb. nr	Struktur	Navn
127		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-3-methyl-1,2,4-oxa-diazol-5-karboksamid
128		3-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,2,4-oxadiazol-5-karboksamid
129		N-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-3-methylisoksazol-4-karboksamid
130		2-methyl-N-(5-(3-methyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)isonikotinamid
131		(R)-2-methyl-N-(5-(3-methyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)isonikotinamid

Forb. nr	Struktur	Navn
132		N-(5-(3-(difluormethyl)-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-2-methylisonikotinamid
133		(R)-N-(5-(3-(difluormethyl)-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-2-methylisonikotinamid
134		2-methyl-N-(5-(2-methyl-oxazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-isonikotinamid
135		(R)-2-methyl-N-(5-(2-metyl-oxazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-isonikotinamid
136		(R)-2-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2H-tetrazol-5-karboksamid
137		2-methyl-N-(5-(5-methyl-isoxazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-isonikotinamid

Forb. nr	Struktur	Navn
		inden-1-yl)-isonikotinamid
138		(R)-2-methyl-N-(5-(5-metylisoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)isonikotinamid
139		(R)-2-methyl-N-(5-(5-metyloksazol-2-yl)-2,3-dihydro-1H-inden-1-yl)isonikotinamid
140		2-methyl-N-(5-(5-methyl-oksazol-2-yl)-2,3-dihydro-1H-inden-1-yl)isonikotinamid
141		(R)-N-(5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-2H-tetrazol-5-karboksamid
14		(R)-N-(5-(5-isopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-2H-tetrazol-5-karboksamid

Forb. nr	Struktur	Navn
143		(R)-N-(5-(5-syklbutyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-2H-tetrazol-5-karboksamid
144		(R)-N-(5-(metoksy-metyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-2H-tetrazol-5-karboksamid
145		2-methyl-N-(5-(2-methyl-oksazol-4-yl)-2,3-dihydro-1H-inden-1-yl)-isonikotinamid
146		(R)-2-methyl-N-(5-(2-metyloksazol-4-yl)-2,3-dihydro-1H-inden-1-yl)-isonikotinamid
147		(R)-2-methyl-N-(5-(2-methyl-2H-tetrazol-5-yl)-2,3-dihydro-1H-inden-1-yl)isonikotinamid

Forb. nr	Struktur	Navn
148		2-methyl-N-(5-(2-methyl-2H-tetrazol-5-yl)-2,3-dihydro-1H-inden-1-yl)isonikotinamid
149		(S)-2-methyl-N-(5-(2-methyl-2H-tetrazol-5-yl)-2,3-dihydro-1H-inden-1-yl)isonikotinamid
150		(R)-N-(5-(5-syklobutyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-4-karboksamid
151		(R)-N-(5-(5-syklobutyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,5-dimethyl-1H-pyrazol-4-karboksamid
152		(R)-N-(5-(5-isopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-4-karboksamid






Forb. nr	Struktur	Navn
153		(R)-N-(5-(5-syklpropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,5-dimethyl-1H-pyrazol-4-karboksamid
154		(R)-N-(5-(5-syklpropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-4-karboksamid
164		(R)-4-methyl-N-(5-(5-methyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4H-1,2,4-triazol-3-karboksamid
165		(R)-N-(5-(5-(difluormethyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-methyl-4H-1,2,4-triazol-3-karboksamid
168		N-(5-(5-(difluormethyl)-isoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-N-(2-methylpyridin-4-yl)methylcarbamoyl






Forb. nr	Struktur	Navn
		yI)-2-metylisonikotinamid
169		(R)-N-(5-(5-(difluormethyl)isoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methylisonikotinamid
170		N-(5-(3-(difluormethyl)isoksazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-2-methylisonikotinamid
171		(R)-N-(5-(3-(difluormethyl)isoksazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-2-methylisonikotinamid
172		(R)-2-methyl-N-(5-(4-metyloksazol-2-yl)-2,3-dihydro-1H-inden-1-yl)-isonikotinamid
173		2-methyl-N-(5-(4-metyl-oksazol-2-yl)-2,3-dihydro-1H-inden-1-yl)-isonikotinamid
174		1-metyl-N-((1R)-5-(5-(oksetan-2-yl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-

Forb. nr	Struktur	Navn
		inden-1-yl)-1H-pyrazol-5-karboksamid
175		(R)-N-(5-(5-(metoksy-methyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-5-karboksamid
176		(R)-N-(5-(5-(metoksy-methyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methylisonikotinamid
177		(R)-N-(5-(5-(metoksy-methyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-methyl-oxazol-5-karboksamid
178		(R)-N-(5-(5-(metoksy-methyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-4-karboksamid

Forb. nr	Struktur	Navn
179		(R)-N-(5-(5-(metoksy-metyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-5-karboksamid
180		(R)-N-(5-(5-(metoksy-metyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2,4-dimethyl-1H-pyrazol-5-karboksamid
181		(R)-N-(5-(5-(metoksy-metyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,5-dimethyl-1H-pyrazol-4-karboksamid
182		(R)-N-(5-(5-(metoksy-metyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-4-karboksamid
183		(R)-N-(5-(5-ethyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-1H-pyrazol-4-karboksamid

Forb. nr	Struktur	Navn
		2H-tetrazol-5-karboksamid
184		(R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-4-karboksamid
185		(R)-N-(5-(5-syklopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-4-karboksamid
186		(R)-N-(5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-4-karboksamid
189		(R)-N-(5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-tetrazol-5-karboksamid

Forb. nr	Struktur	Navn
194		(R)-1,3-dimethyl-N-(5-(3-methyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
201		(R)-1,3-dimethyl-N-(5-(3-methyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
202		(R)-2-methyl-N-(5-(3-methyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)oksazol-5-karboksamid
203		(R)-2-methyl-N-(5-(3-methyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-2H-tetrazol-5-karboksamid
20		(R)-1-methyl-N-(5-(3-methyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid

Forb. nr	Struktur	Navn
213		(R)-N-(5-(3-(difluoromethyl)-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-5-karboksamid
214		(R)-N-(5-(3-(difluoromethyl)-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1,3-dimethyl-1H-pyrazol-4-karboksamid
215		(R)-N-(5-(3-(difluoromethyl)-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-5-oxazol-5-karboksamid
216		(R)-N-(5-(3-(difluoromethyl)-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-2H-tetrazol-5-karboksamid
217		(R)-N-(5-(3-(difluoromethyl)-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-5-karboksamid

Forb. nr	Struktur	Navn
		pyrazol-5-karboksamid
240		(R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-5-karboksamid
241		(R)-N-(5-(5-syklopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-5-karboksamid
252		(R)-2-methyl-N-(5-(5-metylisoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2H-tetrazol-5-karboksamid
253		(R)-N-(5-(5-ethyl-isoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-2H-tetrazol-5-karboksamid
254		(R)-N-(5-(3-ethyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-5-karboksamid






Forb. nr	Struktur	Navn
		1H-pyrazol-4-karboksamid
255		(R)-N-(5-(3-ethyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1,5-dimethyl-1H-pyrazol-4-karboksamid
256		(R)-N-(5-(3-ethyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-2-methyl-2H-tetrazol-5-karboksamid
257		(R)-N-(5-(3-ethyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-5-karboksamid
258		(R)-N-(5-(3-syklopropyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-4-karboksamid
259		(R)-N-(5-(3-syklopropyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1,5-dimethyl-1H-pyrazol-4-karboksamid

Forb. nr	Struktur	Navn
		pyrazol-4-karboksamid
260		(R)-N-(5-(3-syklopropyl-1,2,4-oksadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-2-metyl-2H-tetrazol-5-karboksamid
261		(R)-N-(5-(3-syklopropyl-1,2,4-oksadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1-metyl-1H-pyrazol-5-karboksamid
263		(R)-1-metyl-N-(5-(3-metyl-1,2,4-oksadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
264		(R)-1,5-dimetyl-N-(5-(3-metyl-1,2,4-oksadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid

Forb. nr	Struktur	Navn
276		(R)-N-(5-(3-(difluoromethyl)-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-4-karboksamid
277		(R)-N-(5-(3-(difluoromethyl)-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-1,5-dimethyl-1H-pyrazol-4-karboksamid
278		etyl(R)-(5-(3-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat
279		isopropyl(R)-(5-(3-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat
280		isobutyl(R)-(5-(3-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat
281		syklobutyl(R)-(5-(3-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat







Forb. nr	Struktur	Navn
		dihydro-1H-inden-1-yl)-karbamat
282		metyl(R)-(5-(5-(difluor-methyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat
283		(R)-N-(5-(5-(difluor-methyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)propionamid
284		(R)-N-(5-(5-(difluor-methyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)isobutyramid
285		(R)-N-(5-(5-(difluor-methyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metoksyacetamid
286		(R)-N-(5-(5-(difluor-methyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)acetamid






Forb. nr	Struktur	Navn
287		(R)-N-(5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)cyclopentanekarboksamid
288		(R)-N-(5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)cyclobutanekarboksamid
290		(R)-N-(5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-hydroksy-2-metylpropanamid
291		azetidin-3-yl(R)-(5-(5-(difluormethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-karbamat
293		N-((R)-5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)tetrahydro-furan-2-karboksamid

Forb. nr	Struktur	Navn
294		N-((R)-5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)tetrahydro-furan-3-karboksamid
300		(R)-N-(5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)pyrrolidin-1-karboksamid
301		(R)-N-(5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)morfolin-4-karboksamid
302		(R)-N-(5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-methylpiperazin-1-karboksamid
303		methyl(R)-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat






Forb. nr	Struktur	Navn
304		metyl(R)-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat
305		metyl(R)-(5-(5-syklo-propyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat
306		metyl(R)-(5-(5-(metoksymetyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat
307		metyl(R)-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat
309		(R)-N-(5-(5-(difluor-metyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)syklobutan-karboksamid
310		(R)-N-(5-(5-(difluor-metyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)syklopropan-karboksamid

Forb. nr	Struktur	Navn
315		(R)-N-((R)-5-(5-syklop-ropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-okso-azetidin-2-karboksamid
316		(S)-N-((R)-5-(5-syklo-propyl-1,2,4-oksa-diazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-okso-azetidin-2-karboksamid
317		(R)-N-(5-(5-ethyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-en-1-yl)propionamid
318		(R)-N-(5-(5-syklo-propyl-1,2,4-oksa-diazol-3-yl)-2,3-dihydro-1H-inden-1-yl)syklopropan-karboksamid
319		syklobutyl(R)-(5-(5-metyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat

Forb. nr	Struktur	Navn
320		isobutyl(R)-(5-(5-metyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat
321		syklobutyl(R)-(5-(5-etil-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat
322		isobutyl(R)-(5-(5-etil-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat
323		syklopropylmetyl(R)-(5-(5-etil-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-karbamat
324		2-metoksyetyl(R)-(5-(5-etil-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-karbamat
325		syklopentyl(R)-(5-(5-etil-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat

Forb. nr	Struktur	Navn
326		syklopropylmetyl(R)-(5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-karbamat
327		2-metoksyetyl(R)-(5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-karbamat
328		syklopentyl(R)-(5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-karbamat
329		(R)-N-(5-(5-etyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methylsyklopropan-1-karboksamid
330		(R)-N-(5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methylsyklopropan-1-karboksamid

Forb. nr	Struktur	Navn
331		(R)-1-acetyl-N-((R)-5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-azetidin-2-karboksamid
332		(S)-1-acetyl-N-((R)-5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-azetidin-2-karboksamid
333		2,2-difluoretil(R)-(5-(5-ethyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-karbamat
334		2,2-difluoretil(R)-(5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-karbamat
335		(R)-N-((R)-5-(5-ethyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-5-oksopyrrolidin-2-karboksamid
336		(R)-N-((R)-5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-






Forb. nr	Struktur	Navn
		inden-1-yl)-5-oksopyrrolidin-2-karboksamid
337		(S)-N-((R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-5-oxopiperidin-2-karboksamid
338		(S)-N-((R)-5-(3-sykl-propyl-1,2,4-oxa-diazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-5-oxopiperidin-2-karboksamid
345		metyl(R)-(5-(5-ethyl-isoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-karbamat
350		metyl(R)-(5-(3-sykl-propyl-1,2,4-oxa-diazol-5-yl)-2,3-dihydro-1H-inden-1-yl)-karbamat
351		(R)-N-((R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-oxopiperidin-4-karboksamid

Forb. nr	Struktur	Navn
352		N-((R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-6-oxo-piperidin-3-karboksamid
353		N-((R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methylpiperidin-2-karboksamid
354		N-((R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-6-oxopiperidin-2-karboksamid
355		(S)-N-((R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-oxopiperidin-4-karboksamid
356		(R)-N-((R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)morfolin-3-karboksamid
357		oksetan-3-yl (R)-((5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)carbamoyl)cyclobutene

Forb. nr	Struktur	Navn
		dihydro-1H-inden-1-yl)karbamat
358		oksetan-3-ylmetyl (R)-(5-(5-ethyl-1,2,4-oxadiazo-3-yl)-2,3-dihydro-1H-inden-1-yl)-karbamat
359		2-metoksy-2-methyl-propyl(R)-(5-(5-ethyl-1,2,4-oxadiazo-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat
360		(1-acetylazetidin-3-yl)-methyl(R)-(5-(5-ethyl-1,2,4-oxadiazo-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamat
361		methyl(R)-3-(((5-(5-ethyl-1,2,4-oxadiazo-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamoyl)-oksy)methyl)azetidin-1-karboksylat
362		(1-karbamoylazetidin-3-yl)methyl(R)-(5-(5-ethyl-1,2,4-oxadiazo-3-yl)-2,3-

Forb. nr	Struktur	Navn
		dihydro-1H-inden-1-yl)karbamat
363		(1-(methylcarbamoyl)-azetidin-3-yl)methyl(R)-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-karbamat
366		(R)-1-methyl-N-(5-(pyrimidin-2-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
367		(R)-1-methyl-N-(5-(pyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
368		(R)-1-methyl-N-(5-(pyrazin-2-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
369		(R)-1-methyl-N-(5-(pyridazin-4-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid

Forb. nr	Struktur	Navn
370		(R)-1-methyl-N-(5-(tiazol-2-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
371		(R)-1-methyl-N-(5-(5-methyltiazol-2-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
372		(R)-1-methyl-N-(5-fenyl-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
375		(R)-1-methyl-N-(5-(6-metylpyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
376		(R)-1-methyl-N-(5-(5-methylpyridin-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
377		(R)-1-methyl-N-(5-(6-methylpyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid

Forb. nr	Struktur	Navn
		pyrazol-5-karboksamid
378		(R)-1-methyl-N-(5-(4-methylpyrimidin-2-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
379		(R)-1-methyl-N-(5-(2-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
380		(R)-1-methyl-N-(5-(4-methylpyridin-2-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
381		(R)-1-methyl-N-(5-(6-methylpyrimidin-4-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
382		(R)-1-methyl-N-(5-(6-methylpyrazin-2-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid

Forb. nr	Struktur	Navn
383		(R)-1-methyl-N-(5-(5-methylpyridazin-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
384		(R)-1-methyl-N-(5-(6-methylpyridazin-4-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid
385		(R)-N-(5-(5-ethyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metyloksazol-5-karboksamid
386		(R)-N-(5-(5-ethyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-metyloksazol-5-karboksamid
387		(R)-N-(5-(5-ethyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methylisonikotinamid

Forb. nr	Struktur	Navn
388		(R)-N-(5-(5-syklopropyl-1,2,4-oksa-diazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metyloksazol-5-karboksamid
389		(R)-N-(5-(5-syklopropyl-1,2,4-oksa-diazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methylisonikotinamid
390		(R)-N-(5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-metyloksazol-5-karboksamid
391		(R)-N-(5-(5-isopropyl-1,2,4-oksa-diazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metyloksazol-5-karboksamid
392		(R)-N-(5-(5-isopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-methylisonikotinamid

Forb. nr	Struktur	Navn
393		(R)-N-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-metyloksazol-5-karboksamid
394		(R)-N-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-methyl-1H-pyrazol-4-karboksamid
395		(R)-N-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)acetamid
396		(R)-N-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-3-methyl-1H-pyrazol-4-karboksamid
397		(R)-N-(5-(5-(metoksy-metyl)-1,2,4-oxa-diazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-3-methyl-1H-pyrazol-4-karboksamid

Forb. nr	Struktur	Navn
398		(R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-3-methyl-1H-pyrazol-4-karboksamid
399		(R)-N-(5-(5-syklobutyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-3-methyl-1H-pyrazol-4-karboksamid
400		(R)-3-methyl-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
402		(R)-1-methyl-N-(5-(5-metylisoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
403		(R)-1-methyl-N-(5-(5-metylisoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid

Forb. nr	Struktur	Navn
404		(R)-N-(5-(5-ethyl-isoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metylisonikotinamid
405		(R)-N-(5-(5-ethyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)acetamid
406		(R)-N-(5-(5-syklobutyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)acetamid
407		(R)-N-(5-(5-metyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)acetamid
409		(R)-N-(5-(5-syklobutyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-metyloksazol-5-karboksamid
410		(R)-N-(5-(5-syklobutyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metyloksazol-5-karboksamid

Forb. nr	Struktur	Navn
411		(R)-N-(5-(5-syklobutyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-metyl-1H-pyrazol-4-karboksamid
412		(R)-N-(5-(5-syklobutyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metylisonikotinamid
413		(R)-N-(5-(5-ethyl-isoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-metyl-1H-pyrazol-4-karboksamid
414		(R)-N-(5-(5-ethyl-isoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-metyl-1H-pyrazol-5-karboksamid
415		(R)-N-(5-(5-ethyl-isoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metyloksazol-5-karboksamid

Forb. nr	Struktur	Navn
416		(R)-2-methyl-N-(5-(5-methylisoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)oksazol-5-karboksamid
417		(R)-N-(5-(5-ethyl-isoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-metyloksazol-5-karboksamid
418		(R)-4-methyl-N-(5-(5-methylisoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)oksazol-5-karboksamid
419		(R)-N-(5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-acetamid
420		(R)-N-(5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-3-metyl-1H-pyrazol-4-karboksamid
431		(R)-N-(5-(5-ethyl-isoksazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-5-metyl-1H-pyrazol-4-karboksamid

Forb. nr	Struktur	Navn
		pyrazol-4-karboksamid
432		(R)-5-methyl-N-(5-(5-methylisoxazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
435		(R)-2,2-difluor-N-(5-(5-methyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)acetamid
436		(R)-N-(5-(5-ethyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2,2-difluoracetamid
437		(R)-2,2-difluor-N-(5-(5-(metoksymetyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)acetamid
438		(R)-2,2-difluor-N-(5-(5-isopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)acetamid
439		(R)-N-(5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2,2-difluoracetamid

Forb. nr	Struktur	Navn
		yl)-2,2-difluoracetamid
440		(R)-N-(5-(5-syklbutyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2,2-difluoracetamid
448		(R)-N-(5-(5-(difluormetyl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-4-metyloksazol-5-karboksamid
449		(R)-4-methyl-N-(5-(5-methyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)oksazol-5-karboksamid
467		(R)-N-(5-(5-etil-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-(metoksymetyl)-oksazol-4-karboksamid
469		(R)-N-(5-(5-etil-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-imidazol-2-ylmethyl amide

Forb. nr	Struktur	Navn
		pyrazol-4-karboksamid
470		(R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(oksetan-3-yl)-1H-pyrazol-4-karboksamid
471		tert-butyl (R)-3-(4-((5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamoyl)-1H-pyrazol-1-yl)azetidin-1-karboksylat
472		(R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(2-metoksyethyl)-1H-pyrazol-4-karboksamid
473		metyl(R)-2-(4-((5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamoyl)-1H-pyrazol-1-yl)acetat

Forb. nr	Struktur	Navn
474		(R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(2-hydroxyethyl)-1H-pyrazol-4-karboksamid
475		(R)-1-(2-amino-2-oxoethyl)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
476		(R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-karboksamid
477		(R)-1-(1-acetylazetidin-3-yl)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid

Forb. nr	Struktur	Navn
478		(R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(1-(methylsulfonyl)azetidin-3-yl)-1H-pyrazol-4-karboksamid
479		(R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(1-(methylcarbamoyl)azetidin-3-yl)-1H-pyrazol-4-karboksamid
480		methyl(R)-3-(4-((5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamoyl)-1H-pyrazol-1-yl)-azetidin-1-karboksylat
481		(R)-1-(1-karbamoylazetidin-3-yl)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid

Forb. nr	Struktur	Navn
484		(R)-1-(azetidin-3-yl)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
485		1-(2,3-dihydroksypropyl)-N-((R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
486		(R)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-5-metoksy-1H-pyrazol-4-karboksamid
487		(R)-N-(5-(5-metyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
488		(R)-N-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid

Forb. nr	Struktur	Navn
489		(R)-N-(5-(5-syklopropyl-1,2,4-oksa-diazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
490		(R)-N-(5-(metoksy-metyl)-1,2,4-oksa-diazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
495		N-((1S,2S)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2-hydroksy-2,3-dihydro-1H-inden-1-yl)-1-metyl-1H-pyrazol-4-karboksamid
496		N-((1R)-5-(5-(1-hydroksypropan-2-yl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-metyl-1H-pyrazol-5-karboksamid
497		N-((R)-5-(5-((R)-1-hydroksypropan-2-yl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-5-karboksamid

Forb. nr	Struktur	Navn
		1H-inden-1-yl)-1-metyl-1H-pyrazol-5-karboksamid
498		(R)-N-(5-(5-hydroxypropan-2-yl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-metyl-1H-pyrazol-5-karboksamid
499		(R)-N-(5-(isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2H-tetrazol-5-karboksamid
502		(R)-N-(5-(ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2H-tetrazol-5-karboksamid
505		(R)-N-(5-(syklobutyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2H-tetrazol-5-karboksamid

Forb. nr	Struktur	Navn
509		(R)-1-(2-metoksyethyl)-N-(5-(5-methyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
510		(R)-N-(5-(5-syklopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(2-metoksyethyl)-1H-pyrazol-4-karboksamid
511		(R)-N-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(2-metoksyethyl)-1H-pyrazol-4-karboksamid
512		(R)-1-(2-metoksyethyl)-N-(5-(metoksy-metyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid

Forb. nr	Struktur	Navn
513		(R)-N-(5-(5-syklobutyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(2-metoksyethyl)-1H-pyrazol-4-karboksamid
518		N-((1R)-5-(5-(1-hydroksypropan-2-yl)-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-2-metyl-2H-tetrazol-5-karboksamid
520		(R)-1-(2-hydroksyethyl)-N-(5-(5-metyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
521		(R)-N-(5-(5-syklopropyl-1,2,4-oksadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(2-hydroksyethyl)-1H-pyrazol-4-karboksamid

Forb. nr	Struktur	Navn
522		(R)-1-(2-hydroksyethyl)-N-(5-(5-isopropyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
523		(R)-1-(2-hydroksyethyl)-N-(5-(5-(metoksy-metyl)-1,2,4-oxa-diazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
524		(R)-N-(5-(5-syklobutyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(2-hydroksyethyl)-1H-pyrazol-4-karboksamid
527		(R)-N-(5-(5-etyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-vinyl-1H-pyrazol-4-karboksamid

Forb. nr	Struktur	Navn
528		(R)-N-(5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(2-hydroksyethyl)-1H-pyrazol-4-karboksamid
529		(R)-N-(5-(5-(difluoromethyl)-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(2-metoksyethyl)-1H-pyrazol-4-karboksamid
530		(R)-1-(2,2-dimetoksyethyl)-N-(5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1H-pyrazol-4-karboksamid
531		2-(4-(((R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamoyl)-1H-pyrazol-1-yl)propansyre


Forb. nr	Struktur	Navn
532		(R)-2-(4-((5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)karbamoyl)-1H-pyrazol-1-yl)eddksyre
533		N-((R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(1-hydroksypropan-2-yl)-1H-pyrazol-4-karboksamid
538		N-((R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)-2,3-dihydro-1H-inden-1-yl)-1-(2-hydroksypropyl)-1H-pyrazol-4-karboksamid
539		N-[(1R)-5-(5-ethyl-(1,2,4-oxadiazol-3-yl))indanyl][1-((2R)-2,3-dihydroksypropyl)-pyrazol-4-yl]-karboksamid

Forb. nr	Struktur	Navn
540		N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)indanyl][1-((2S)-2,3-dihydroksypropyl)pyrazol-4-yl]karboksamid
541		N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)indanyl][1-((2S)-2-hydroksypropyl)pyrazol-4-yl]karboksamid
542		N-[(1R)-5-(5-ethyl-1,2,4-oxadiazol-3-yl)indanyl][1-((2R)-2-hydroksypropyl)pyrazol-4-yl]karboksamid
543		1-(3-{(1R)-1-[(1-metylpyrazol-4-yl)karbonylamino]indan-5-yl}(1,2,4-oxadiazol-5-yl)-(1S)ethylacetat
546		N-{(1R)-5-[5-(2-metoksyethyl)(1,2,4-oxadiazol-3-yl)]indanyl}(1-metylpyrazol-4-yl)karboksamid

Forb. nr	Struktur	Navn
548		2-(3-{(1R)-1-[(1-methylpyrazol-4-yl)-karbonylamino]indan-5-yl}-1,2,4-oxadiazol-5-yl)ethylacetat
549		N-{(1R)-5-[5-(hydroksyethyl)(1,2,4-oxadiazol-3-yl)]-indanyl}(1-methylpyrazol-4-yl)-karboksamid
550		N-{(1R)-5-[5-((1R)-1-hydroksyethyl)-(1,2,4-oxadiazol-3-yl)]indanyl}(1-methylpyrazol-4-yl)-karboksamid
551		N-{(1R)-5-[5-(metoksyethyl)(1,2,4-oxadiazol-3-yl)]-indanyl}(1-methylpyrazol-4-yl)-karboksamid; og
552		N-{(1R)-5-[5-(2-hydroksyethyl)(1,2,4-oxadiazol-3-yl)]-indanyl}(1-methylpyrazol-4-yl)-karboksamid


eller et farmasøytisk akseptabelt salt derav.

**19.** Forbindelsen ifølge krav 1, hvor forbindelsen er



eller et farmasøytisk akseptabelt salt derav.

- 5   **20.** Forbindelsen ifølge krav 1, hvor forbindelsen er



eller farmasøytisk akseptabelt salt derav.

- 10   **21.** En farmasøytisk sammensetning som omfatter en forbindelse i henhold til et hvilket som helst av krav 1 til 20, eller et farmasøytisk akseptabelt salt derav, og en farmasøytisk akseptabel eksipiens.
- 15   **22.** Forbindelsen ifølge et hvilket som helst av krav 1-20, eller et farmasøytisk akseptabelt salt derav, eller den farmasøytiske sammensetningen ifølge krav 21, for anvendelse i en fremgangsmåte for å behandle hjertesykdom i et individ med behov for det.
- 20   **23.** Forbindelsen, eller et farmasøytisk akseptabelt salt derav, eller den farmasøytiske sammensetningen for anvendelse i henhold til krav 22, hvor
- 25       (a) hjertesykdommen er valgt fra gruppen som består av diastolisk dysfunksjon, primær eller sekundær restriktiv kardiomyopati, hjerteinfarkt og angina pectoris, obstruksjon av venstre ventrikkels utstrømningskanal, hypertensiv hjertesykdom, medfødt hjertesykdom, hjerteiskemi, koronar hjertesykdom, diabetisk hjertesykdom, kongestiv hjertesvikt, høyre hjertesvikt, kardiorenalt syndrom, og infiltrativ kardiomyopati, eller

(b) hjertesykdommen er eller er relatert til én eller flere tilstander valgt fra gruppen som består av hjerte-alderdom, diastolisk dysfunksjon på grunn av aldring, venstre ventrikulærhypertrofi og konsentrisk venstre ventrikulær-remodellering.

5

**24.** Forbindelsen, eller et farmasøytisk akseptabelt salt derav, eller den farmasøytiske sammensetningen for anvendelse i henhold til krav 22, hvor hjertesykdommen er hypertrofisk kardiomyopati (HCM), eventuelt hvor HCM-en er obstruktiv eller ikke-obstruktiv eller er assosiert med en sarkomerisk og/eller 10 ikke-sarkomerisk mutasjon.

15

**25.** Forbindelsen, eller et farmasøytisk akseptabelt salt derav, eller den farmasøytiske sammensetningen for anvendelse i henhold til krav 22, hvor hjerte-sykdommen er hjertesvikt med bevart ejeksjonsfraksjon (HFpEF).

20

**26.** Forbindelsen ifølge et hvilket som helst av krav 1-20, eller et farmasøytisk akseptabelt salt derav, eller den farmasøytiske sammensetningen ifølge krav 21, for anvendelse i en fremgangsmåte for å behandle en sykdom eller tilstand i et individ med behov for det, hvor sykdommen eller tilstanden er assosiert med liten 25 venstre ventrikkelhule, hulrom obliterationsj, hyperdynamisk venstre ventrikkelkontraksjon, myokardiskemi, eller hjertefibrose.

25

**27.** En farmasøytisk sammensetning som omfatter forbindelsen i henhold til krav 20, eller et farmasøytisk akseptabelt salt derav, og en farmasøytisk akseptabel eksipiens.

30

**28.** Forbindelsen ifølge krav 20, eller et farmasøytisk akseptabelt salt derav, eller den farmasøytiske sammensetningen ifølge krav 27, for anvendelse i en fremgangsmåte for å behandle hjertesykdom hos et individ med behov for det.

**29.** Forbindelsen, eller et farmasøytisk akseptabelt salt derav, eller den farmasøytiske sammensetningen for anvendelse i henhold til krav 28, hvor hjerte-sykdommen er hypertrofisk kardiomyopati (HCM).

**30.** Forbindelsen, eller et farmasøytisk akseptabelt salt derav, eller den farmasøytiske sammensetningen for anvendelse i henhold til krav 28, hvor hjertesykdommen er hjertesvikt med bevart ejeksjonsfraksjon (HFpEF).